Abstract Number: 1939 • 2018 ACR/ARHP Annual Meeting
Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail
Background/Purpose: Patients with refractory rheumatoid arthritis (RA) have T-cell dysfunction that associates the activation of mTOR that is inhibited by rapamycin, which has been developed…Abstract Number: 2054 • 2018 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of autoantibodies like rheumatoid factor (RF), anti-cyclic citrullinated peptide-2 (anti-CCP2), & anti-carbamylated protein (anti-CarP) antibodies. It…Abstract Number: 2344 • 2018 ACR/ARHP Annual Meeting
Treatment Modes in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
Background/Purpose: Treatment recommendations in RA emphasize shared decision-making,1 but little is known about patient (pt) perspectives. Through qualitative research, we aim to understand pt preferences…Abstract Number: 134 • 2018 ACR/ARHP Annual Meeting
Exploration of T-Cell Signatures Following TCR Stimulation Using Single Cell RNA-Seq to Inform Treatment Response Studies in Rheumatoid Arthritis
Background/Purpose: For rheumatoid arthritis (RA), as with many other rheumatic diseases, the importance of determining which therapy will work best, early in disease, to prevent…Abstract Number: 2510 • 2018 ACR/ARHP Annual Meeting
A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the effects…Abstract Number: 555 • 2018 ACR/ARHP Annual Meeting
Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function
Background/Purpose: The aim of this study was to evaluate three year outcomes of patients with elderly-onset RA (EORA) who were treated with a therapeutic strategy…Abstract Number: 2538 • 2018 ACR/ARHP Annual Meeting
Rapamycin Induces Remission in Patients with Newly Diagnosed Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints.We found that there was an imbalance between Th17 and Treg…Abstract Number: 561 • 2018 ACR/ARHP Annual Meeting
U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination
Background/Purpose: The U-Act-Early trial was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission, with step-up…Abstract Number: 2540 • 2018 ACR/ARHP Annual Meeting
Effect of Buccal Hygiene on the Systemic Activity of Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Background/Purpose: Good evidence suggests a relationship between rheumatoid arthritis (RA) and periodontitis. We aimed to investigate if a good oral hygiene could improve activity of…Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
Background/Purpose: Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents. As previous studies have…Abstract Number: 2543 • 2018 ACR/ARHP Annual Meeting
Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Background/Purpose: CT-P13 is a biosimilar prescribed in a number of countries for indications approved for the reference infliximab (RINF) including rheumatoid arthritis (RA), ankylosing spondylitis…Abstract Number: 1079 • 2017 ACR/ARHP Annual Meeting
Treat to Target Adherence Measurement Tool Performance in Rheumatoid Arthritis
Background/Purpose: The purpose of the T2T approach in RA is to achieve remission or LDA according to results from objective activity measurements. This strategy has…Abstract Number: 1333 • 2017 ACR/ARHP Annual Meeting
Mortality of Tumor Necrosis Factor Transgenic Arthritic Mice with Interstitial Lung Disease Occurs with Pulmonary Arteriole Thickening and Right Ventricular Hypertrophy but Is Not Associated with Inducible Nitric Oxide Synthase Dependent Inflammatory Cell Infiltration
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) occurs in up to 15% of RA patients, whose median survival expectancy after diagnosis is only 2.6…Abstract Number: 1349 • 2017 ACR/ARHP Annual Meeting
Treat to Target: What’s the Target?
Background/Purpose: The 2015 ACR RA treatment guidelines focus on measuring disease activity and provide a guideline driven treat to target strategy. We hope to understand…Abstract Number: 1418 • 2017 ACR/ARHP Annual Meeting
The Value of Adalimumab Trough Levels and Clinical Assessments in Predicting Clinical Response in Patients with Established Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Background/Purpose: Low trough levels of the tumor necrosis factor inhibitor, adalimumab (ADL), and anti-ADL antibodies (AAA) were reported to be correlated with lack of response…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 10
- Next Page »